Tag: Dr Hugh Sampson
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
AllerGenis Lauds Study Results of New, More Accurate Blood Test for...
"Test brings us one step closer to eliminating the need to subject patients to an oral food challenge."
AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope...
VeriMAP Peanut Diagnostic has a 93% concordance with food challenge results providing a diagnosis with greater certainty.
Egg OIT Leads to More Rapid Allergy Desensitization Than Baked-Egg Products
Study suggests oral immunotherapy may lead to higher sustained unresponsiveness to egg for baked-egg tolerant children.
Test is 87% Accurate at Determining Outcome to Milk OIT
Using a growing database of patient reactivity signatures can better predict milk-allergic patient outcomes compared to traditional methods.
Mount Sinai and AllerGenis Announce Partnership to Bring Novel, Precision Diagnostics...
The technology will provide an improved method for detecting, assessing, and monitoring food allergies in patients.
DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy
"This submission represents a significant step forward for those families living with peanut allergy."
NIH: Introduce Peanuts to High-Risk Infants Early
Based on the findings of the LEAP study, an expert panel recommends that peanuts be introduced to infants as early as 4 months of age.
Incidence of Food Allergies Rising? Don't Jump to Conclusions, Says Report
Report calls on authorities to conduct a large-scale study to determine the true prevalence of food allergies.
Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial
The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.
